Today’s AI Top Pick: SPRO

7/21/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · ContrarianSPROBUY NOW9.1 / 107/21/2026

SPRO is the cleanest contrarian bounce setup in this pool because the thesis is backed by a real, material positive catalyst that dropped mid-selloff: on July 15 Innovent licensed IBI355 rights to Spero for up to $1.1bn, and on July 14 Seeking Alpha upgraded to 'Buy' on the Utebzi royalty deal + SP001 in-licensing. That is not a hopeful forecast — that is cash and pipeline optionality landing while the stock is oversold (RSI 23.64, 1d drawdown -34.92%, 4h drawdown -33.61%). The market is still digesting the news at the bottom of the 21-bar range (pos_in_21bar_range_pct 0 on 1d, 8.36 on 4h), which is exactly the 'exhausted selling on a re-rating catalyst' pattern this lens is designed to catch. Multi-timeframe alignment is the best in the group on the horizons that matter. 1h fc_short +82.52% / fc_mid +79.66% / fc_long +70.73%, 4h +77.5 / +67.22 / +65.68, and 1d +31.81 / +61.47 / +46.19. Only the 1wk is soft (+38.56 / +11.97 / +0.84), which actually argues for a tradeable bounce rather than a full trend reversal — appropriate for a contrarian-bounce lens. Bullish probability is 1.0, near_term_bullish is 1.0, and it is NOT sitting at the top of the range (unlike IONQ at 73% 1h position or CRML at 62%). The score of 39.7 with an expected_return_pct of 35.4% is conservative given the licensing deal. Fundamentals are the real differentiator. fundamental_score is +8 — the highest in the pool. Trailing pe 5.91, fwdPe 2.15, roe 35.12, profitMargin 27.82, salesYoY +93.5%, epsNextY +331, debt/equity 0.05, and analyst targetUpsidePct 177.8. This is not a story-only microcap like LUCY, ANY, or SST; there is actual profitability and now a funded pipeline. Compare to IBM (fundamental_score 4.75) which just got a 'surprise profit warning' with targets cut and reports earnings tomorrow — that's the exact landmine this lens tells us to avoid. CRML (Cantor Speculative Buy $18) is a legitimate #2 but sits higher in its range and has no cash-in-the-door event. Why TODAY vs waiting: the Innovent deal and Seeking Alpha thesis both hit within the last week while price is still pinned at the range floor — that gap between fresh positive catalyst and unrecovered price is the entry. Waiting risks the 4h/1h forecasts (short-horizon 77-82% projections) resolving before you're in. The 1wk softness gives a natural stop below recent lows for tight risk management.

Entry zone

$1.42 - $1.52 (current $1.48, buy into any dip toward 4h/1d floor near $1.40-$1.45)

Stop loss

$1.24 (below the -34.92% 1d 21-bar low; ~16% risk from mid-entry)

First target

$1.95 - $2.05 (fc_short_1d +31.8% / fc_short_4h +77.5%; reclaim of prior consolidation)

Longer target

$2.40 - $2.60 (fc_mid_1d +61.5%; fills the gap toward pre-selloff level, ~65% upside)

Risks

1wk forecast fades to +0.84% fc_long — this is a bounce trade, not a trend trade; take profits into strength
Recom is 3.0 (Hold) despite fundamentals — sell-side hasn't upgraded post-Innovent deal yet, so no analyst tailwind to force short covering
Small-cap healthcare ($83M market cap) with 6.69% short float can gap violently in either direction on any pipeline update
Position in 21-bar range is 0 on the 1d — if $1.40 breaks, next support is thin and stop must be honored
China licensing deals (Innovent/AstraZeneca cited together in BioPharma Dive headline) carry geopolitical/regulatory execution risk on milestone payments

Honorable mentions

CRMLCantor Fitzgerald initiated Speculative Buy with $18 PT on July 14; MTF alignment is strong (1h fc +75.9/+79.1/+81.6, 4h +57.7/+63.3/+62.6, 1d +29.4/+38.4/+77.5); rare-earth/critical minerals tailwind from Trump Greenland commentary. Held back from #1 because 1h position is 62.87% (already bounced intraday) and no earnings/cash catalyst like SPRO.

HYPRClean product catalyst — European launch of next-gen Swoop portable MRI with Optive AI on July 16. 1h fc +58.2/+55.3/+52.8 and 4h +33.9/+36.0/+36.6 with pos_in_21bar 3.4% on 4h. Fundamentals softer (profitMargin -226.88) so smaller position size warranted; recom 1.0 helps.

Full ranking (22)

#	Symbol	Verdict	Score	Read
1	SPRO	BUY NOW	9.1	Oversold (RSI 23.64) into a $1.1bn Innovent licensing deal with fundamental_score 8 and 1h/4h/1d forecasts all above +30%.
2	CRML	BUY NOW	7.6	Cantor Speculative Buy $18 PT + all three sub-weekly TFs forecasting +29% to +82%; critical minerals policy tailwind.
3	HYPR	BUY NOW	7.0	European Swoop MRI launch catalyst with 1h fc +58% and 4h +34%, near the 21-bar floor (pos 3.4% on 4h).
4	LEGN	BUY PULLBACK	6.7	Real revenue biotech with JPM/RBC coverage and 1wk fc +35.8/+41.6/+76.5, but 1h already at 25% of range — wait for dip.
5	AKTX	BUY PULLBACK	6.4	Maxim upgrade to Buy $30 PT is huge vs ~$10.66 price, but 6M-ADS resale prospectus caps upside with dilution overhang.
6	BESS	BUY NOW	6.2	FPUSA Wildfire BESS project win, fundamental_score 6, recom 1.0; 1d fc +43/+79/+40 with 1d position at 0.
7	GTBP	WAIT	5.8	All TFs at 0% of range with fc +34/+27/+35, but roe -1446 and no revenue disclosed — pure lottery ticket.
8	IONQ	BUY PULLBACK	5.6	1h position at 73% is chase territory and 1wk forecast is negative (-13/-36/-21) — wait for reset.
9	CALC	WAIT	5.5	FDA cleared Auxora trial continuation is positive, but $49M private placement financing on June 24 is fresh dilution.
10	LTRN	WAIT	5.4	ZetaOmics launch plus 1wk fc +19/+26/+50, but only 2 TFs available and 4h fc_long is -6.95%.
11	LUCY	WAIT	5.2	Claude AI integration is a real catalyst but $3M warrant exercise = dilution and $4.8M market cap is untradeable size.
12	ASPI	WAIT	5.0	Strong 1h/4h/1d forecasts +55-70% but shelf registration + 23.2M share resale prospectus caps the bounce.
13	GRRR	WAIT	4.9	$125M convertible note offering just priced — dilution overhang despite Simply Wall St 'undervalued' take.
14	ANY	WAIT	4.7	Huge 1d fc +134/+204/+186 but pivoting to DarkHorse crypto/mining rebrand — narrative shift, not fundamentals.
15	INV	WAIT	4.5	ps 80.45 and profitMargin -5226% is a hard pass on fundamentals despite CEO succession and salesYoY +126.8%.
16	IVVD	WAIT	4.3	FDA advance termination of PEMGARDA EUA is a material negative; BTIG Buy is now backward-looking.
17	SST	WAIT	4.2	Big fc numbers (+72 to +212 on 1wk) but 1wk position 0, insider buying only, and -31% salesYoY — broken business.
18	TROLL-USD	WAIT	4.0	Bullish_prob 1 but no MTF detail provided — crypto memecoin, no way to size risk.
19	IBM	AVOID	3.8	Surprise profit warning July 20, analyst PT cuts, earnings tomorrow — landmine despite fundamental_score 4.75.
20	LESL	AVOID	3.5	StockStory '3 Reasons to Avoid LESL', ps 0.02, salesYoY -7.46, and 4h fc_long already turning negative (-19.7%).
21	ILLR	AVOID	3.2	Company forced to issue 'no material development' statement addressing volatility, plus prior Nasdaq compliance skirmish on share issuance.
22	RXRX	AVOID	3.0	Only one timeframe (4h) available, bullish_prob null, and three consecutive 'fell more than market' headlines — no conviction.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord